# Marco Presta

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 333 papers | 15,930 citations | 69 h-index | 112 g-index |
| 346 ext. papers | 17,113 ext. citations | 6.4 avg, IF | 6.15 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 333 | FGFR blockade by pemigatinib treats naïve and castration resistant prostate cancer. *Cancer Letters*, **2021**, 526, 217-224 | 9.9 | 2 |
| 332 | Oncosuppressive and oncogenic activity of the sphingolipid-metabolizing enzyme α-galactosylceramidase.. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2021**, 1877, 188675 | 11.2 | 0 |
| 331 | Quantification of Tumor Vasculature by Analysis of Amount and Spatial Dispersion of Caliber-Classified Vessels. *Methods in Molecular Biology*, **2021**, 2206, 151-178 | 1.4 | |
| 330 | Simultaneously characterization of tumoral angiogenesis and vasculogenesis in stem cell-derived teratomas. *Experimental Cell Research*, **2021**, 400, 112490 | 4.2 | 2 |
| 329 | Expression of activated VEGFR2 by R1051Q mutation alters the energy metabolism of Sk-Mel-31 melanoma cells by increasing glutamine dependence. *Cancer Letters*, **2021**, 507, 80-88 | 9.9 | 6 |
| 328 | Specific targeting of the KRAS mutational landscape in myeloma as a tool to unveil the elicited antitumor activity. *Blood*, **2021**, 138, 1705-1720 | 2.2 | 3 |
| 327 | The FGF/FGFR system in the physiopathology of the prostate gland. *Physiological Reviews*, **2021**, 101, 569-610 | 47.9 | 5 |
| 326 | A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. *Cancer Letters*, **2021**, 496, 84-92 | 9.9 | 4 |
| 325 | Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88. *Blood*, **2021**, 137, 2495-2508 | 2.2 | 1 |
| 324 | Avian Reovirus P17 Suppresses Angiogenesis by Promoting DPP4 Secretion. *Cells*, **2021**, 10, | 7.9 | 2 |
| 323 | Endogenous Long Pentraxin 3 Exerts a Protective Role in a Murine Model of Pulmonary Fibrosis. *Frontiers in Immunology*, **2021**, 12, 617671 | 8.4 | 3 |
| 322 | VEGF-Independent Activation of Müller Cells by the Vitreous from Proliferative Diabetic Retinopathy Patients. *International Journal of Molecular Sciences*, **2021**, 22, | 6.3 | 6 |
| 321 | α-Galactosylceramidase in cancer: friend or foe?. *Trends in Cancer*, **2021**, 7, 974-977 | 12.5 | 1 |
| 320 | Vitreous from idiopathic epiretinal membrane patients induces glial-to-mesenchymal transition in Müller cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2021**, 1867, 166181 | 6.9 | 0 |
| 319 | Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma. *European Journal of Medicinal Chemistry*, **2021**, 221, 113529 | 6.8 | 1 |
| 318 | Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress. *International Journal of Molecular Sciences*, **2020**, 21, | 6.3 | 12 |
| 317 | Gene expression analysis identifies two distinct molecular clusters of idiopatic epiretinal membranes. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2020**, 1866, 165938 | 6.9 | 5 |

| | | | |
|---|---|---|---|
| 316 | D-Peptide analogues of Boc-Phe-Leu-Phe-Leu-Phe-COOH induce neovascularization via endothelial N-formyl peptide receptor 3. *Angiogenesis*, **2020**, 23, 357-369 | 10.6 | 6 |
| 315 | Long-Pentraxin 3 Affects Primary Cilium in Zebrafish Embryo and Cancer Cells via the FGF System. *Cancers*, **2020**, 12, | 6.6 | 4 |
| 314 | Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer. *Cancer Research*, **2020**, 80, 1564-1577 | 10.1 | 5 |
| 313 | FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress. *Cancer Research*, **2020**, 80, 2340-2354 | 10.1 | 18 |
| 312 | Zebrafish embryo as an experimental model to study tumor angiogenesis **2020**, 129-145 | | 5 |
| 311 | FGF/FGFR Axis-Blockade Leads to Anti-Tumor Activity in Waldenstrom's Macroglobulinemia By Silencing MYD88. *Blood*, **2020**, 136, 43-44 | 2.2 | 0 |
| 310 | Angiogenesis-Inflammation Cross Talk in Diabetic Retinopathy: Novel Insights From the Chick Embryo Chorioallantoic Membrane/Human Vitreous Platform. *Frontiers in Immunology*, **2020**, 11, 581288 | 8.4 | 19 |
| 309 | Galactosylceramidase Promotes Melanoma Growth via Modulation of Ceramide Metabolism. *Cancer Research*, **2020**, 80, 5011-5023 | 10.1 | 5 |
| 308 | In Situ DNA/Protein Interaction Assay to Visualize Transcriptional Factor Activation. *Methods and Protocols*, **2020**, 3, | 2.5 | 2 |
| 307 | Human iPSC modelling of a familial form of atrial fibrillation reveals a gain of function of If and ICaL in patient-derived cardiomyocytes. *Cardiovascular Research*, **2020**, 116, 1147-1160 | 9.9 | 27 |
| 306 | Targeting the Endothelin-1 Receptors Curtails Tumor Growth and Angiogenesis in Multiple Myeloma. *Frontiers in Oncology*, **2020**, 10, 600025 | 5.3 | 4 |
| 305 | Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression. *Cancers*, **2019**, 11, | 6.6 | 9 |
| 304 | The Autocrine FGF/FGFR System in both Skin and Uveal Melanoma: FGF Trapping as a Possible Therapeutic Approach. *Cancers*, **2019**, 11, | 6.6 | 7 |
| 303 | PTX3 Modulates Neovascularization and Immune Inflammatory Infiltrate in a Murine Model of Fibrosarcoma. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 8 |
| 302 | Vascular Endothelial Growth Factor in the Vitreous of Proliferative Diabetic Retinopathy Patients: Chasing a Hiding Prey?. *Diabetes Care*, **2019**, 42, e105-e106 | 14.6 | 9 |
| 301 | Atypical Chemokine Receptor 3 Generates Guidance Cues for CXCL12-Mediated Endothelial Cell Migration. *Frontiers in Immunology*, **2019**, 10, 1092 | 8.4 | 3 |
| 300 | Circulating microRNAs and Their Role in Multiple Myeloma. *Non-coding RNA*, **2019**, 5, | 7.1 | 5 |
| 299 | Quantification of 3D Brain Microangioarchitectures in an Animal Model of Krabbe Disease. *International Journal of Molecular Sciences*, **2019**, 20, | 6.3 | 5 |

| | | | |
|---|---|---|---|
| 298 | Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. *Progress in Retinal and Eye Research*, **2019**, 72, 100756 | 20.5 | 47 |
| 297 | VEGFR2 activation mediates the pro-angiogenic activity of BMP4. *Angiogenesis*, **2019**, 22, 521-533 | 10.6 | 18 |
| 296 | Specific Targeting of KRAS Using a Novel High-Affinity KRAS Antisense Oligonucleotide in Multiple Myeloma. *Blood*, **2019**, 134, 3104-3104 | 2.2 | 1 |
| 295 | Overcoming the Supportive Stroma-Induced Proliferation in Waldenstrom's Macroglobulinemia By Selective Inhibition of the FGF/FGF-Receptor Axis. *Blood*, **2019**, 134, 1822-1822 | 2.2 | |
| 294 | Galactosylceramidase Deficiency Causes Bone Marrow Vascular Defects in an Animal Model of Krabbe Disease. *International Journal of Molecular Sciences*, **2019**, 21, | 6.3 | 2 |
| 293 | The nanostructured secretome. *Biomaterials Science*, **2019**, 8, 39-63 | 7.4 | 18 |
| 292 | Zebrafish disease models in hematology: Highlights on biological and translational impact. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2019**, 1865, 620-633 | 6.9 | 9 |
| 291 | N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) inhibits the angiogenic activity of heparin-binding growth factors. *Angiogenesis*, **2018**, 21, 47-59 | 10.6 | 24 |
| 290 | Dendritic cells in inflammatory angiogenesis and lymphangiogenesis. *Current Opinion in Immunology*, **2018**, 53, 180-186 | 7.8 | 22 |
| 289 | Claudin3 is localized outside the tight junctions in human carcinomas. *Oncotarget*, **2018**, 9, 18446-18453 | 3.3 | 4 |
| 288 | Long pentraxin 3: A novel multifaceted player in cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2018**, 1869, 53-63 | 11.2 | 32 |
| 287 | Long Pentraxin 3-Mediated Fibroblast Growth Factor Trapping Impairs Fibrosarcoma Growth. *Frontiers in Oncology*, **2018**, 8, 472 | 5.3 | 12 |
| 286 | Vascular amounts and dispersion of caliber-classified vessels as key parameters to quantitate 3D micro-angioarchitectures in multiple myeloma experimental tumors. *Scientific Reports*, **2018**, 8, 17520 | 4.9 | 5 |
| 285 | Long Pentraxin-3 Modulates the Angiogenic Activity of Fibroblast Growth Factor-2. *Frontiers in Immunology*, **2018**, 9, 2327 | 8.4 | 31 |
| 284 | Future applications of FGF/FGFR inhibitors in cancer. *Expert Review of Anticancer Therapy*, **2018**, 18, 861-872 | 3.52 | 45 |
| 283 | Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathy. *Diabetologia*, **2017**, 60, 719-728 | 10.3 | 26 |
| 282 | FGF Ligand Traps for the Therapy of FGF-Dependent Tumors **2017**, 237-269 | | |
| 281 | Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. *Pharmacology & Therapeutics*, **2017**, 179, 171-187 | 13.9 | 97 |

| | | | |
|---|---|---|---|
| 280 | 3D endothelial cell spheroid/human vitreous humor assay for the characterization of anti-angiogenic inhibitors for the treatment of proliferative diabetic retinopathy. *Angiogenesis*, **2017**, 20, 629-640 | 10.6 | 14 |
| 279 | Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. *Oncogene*, **2017**, 36, 6531-6541 | 9.2 | 18 |
| 278 | The importance of the genomic landscape in Waldenström Macroglobulinemia for targeted therapeutical interventions. *Oncotarget*, **2017**, 8, 35435-35444 | 3.3 | 3 |
| 277 | U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis. *Oncotarget*, **2017**, 8, 44533-44549 | 3.3 | 10 |
| 276 | Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer. *Oncotarget*, **2017**, 8, 82583-82592 | 3.3 | 21 |
| 275 | Evaluation of the Biotoxicity of Tree Wood Ashes in Zebrafish Embryos. *Zebrafish*, **2016**, 13, 449-55 | 2 | 4 |
| 274 | SIGMAR1 Regulates Membrane Electrical Activity in Response to Extracellular Matrix Stimulation to Drive Cancer Cell Invasiveness. *Cancer Research*, **2016**, 76, 607-18 | 10.1 | 34 |
| 273 | Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy. *Pharmacological Research*, **2016**, 107, 172-185 | 10.2 | 52 |
| 272 | Synthetic Site-Selectively Mono-6-O-Sulfated Heparan Sulfate Dodecasaccharide Shows Anti-Angiogenic Properties In Vitro and Sensitizes Tumors to Cisplatin In Vivo. *PLoS ONE*, **2016**, 11, e0159739 | 3.7 | 7 |
| 271 | Monomeric gremlin is a novel vascular endothelial growth factor receptor-2 antagonist. *Oncotarget* , **2016**, 7, 35353-68 | 3.3 | 24 |
| 270 | Endothelial cell dysfunction in globoid cell leukodystrophy. *Journal of Neuroscience Research*, **2016**, 94, 1359-67 | 4.4 | 11 |
| 269 | Zebrafish (Danio rerio) embryo as a platform for the identification of novel angiogenesis inhibitors of retinal vascular diseases. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2016**, 1862, 1291-6 | 6.9 | 28 |
| 268 | Synthesis, Structural Elucidation, and Biological Evaluation of NSC12, an Orally Available Fibroblast Growth Factor (FGF) Ligand Trap for the Treatment of FGF-Dependent Lung Tumors. *Journal of Medicinal Chemistry*, **2016**, 59, 4651-63 | 8.3 | 21 |
| 267 | COSMOS-rice technology abrogates the biotoxic effects of municipal solid waste incinerator residues. *Environmental Pollution*, **2016**, 214, 713-721 | 9.3 | 10 |
| 266 | Therapeutic Potential of Anti-Angiogenic Multitarget N,O-Sulfated E. Coli K5 Polysaccharide in Diabetic Retinopathy. *Diabetes*, **2015**, 64, 2581-92 | 0.9 | 17 |
| 265 | The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. *Expert Opinion on Therapeutic Targets*, **2015**, 19, 1361-77 | 6.4 | 55 |
| 264 | Long-Pentraxin 3 Derivative as a Small-Molecule FGF Trap for Cancer Therapy. *Cancer Cell*, **2015**, 28, 225-39 | 24.3 | 80 |
| 263 | Total reflection X-Ray fluorescence spectroscopy to study Pb and Zn accumulation in zebrafish embryos. *X-Ray Spectrometry*, **2015**, 44, 124-128 | 0.9 | 17 |

| | | | |
|---|---|---|---|
| 262 | Brain angioarchitecture and intussusceptive microvascular growth in a murine model of Krabbe disease. *Angiogenesis*, **2015**, 18, 499-510 | 10.6 | 31 |
| 261 | β3 Integrin Promotes Long-Lasting Activation and Polarization of Vascular Endothelial Growth Factor Receptor 2 by Immobilized Ligand. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2161-71 | 9.4 | 11 |
| 260 | Angiogenic growth factors interactome and drug discovery: The contribution of surface plasmon resonance. *Cytokine and Growth Factor Reviews*, **2015**, 26, 293-310 | 17.9 | 24 |
| 259 | Antiangiogenic Effectiveness of the Urokinase Receptor-Derived Peptide UPARANT in a Model of Oxygen-Induced Retinopathy **2015**, 56, 2392-407 | | 29 |
| 258 | The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors. *Oncotarget*, **2015**, 6, 4633-48 | 3.3 | 9 |
| 257 | A tool for the quantification of radial neo-vessels in chick chorioallantoic membrane angiogenic assays. *Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Annual International Conference*, **2015**, 2015, 763-6 | 0.9 | 1 |
| 256 | A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. *Oncotarget*, **2015**, 6, 13790-802 | 3.3 | 22 |
| 255 | Zebrafish embryo intersegmental vessels: a tool for investigating sprouting angiogenesis. *Methods in Molecular Biology*, **2015**, 1214, 173-84 | 1.4 | 9 |
| 254 | In vitro and ex vivo retina angiogenesis assays. *Angiogenesis*, **2014**, 17, 429-42 | 10.6 | 51 |
| 253 | Biosafe inertization of municipal solid waste incinerator residues by COSMOS technology. *Journal of Hazardous Materials*, **2014**, 279, 311-21 | 12.8 | 25 |
| 252 | Cyclic adenosine monophosphate-response element-binding protein mediates the proangiogenic or proinflammatory activity of gremlin. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 136-45 | 9.4 | 29 |
| 251 | The role of the endothelium in globoid-cell leukodystrophy: unexpected revelations. *Future Neurology*, **2014**, 9, 127-130 | 1.5 | 1 |
| 250 | Molecular cloning and knockdown of galactocerebrosidase in zebrafish: new insights into the pathogenesis of Krabbe's disease. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 665-75 | 6.9 | 17 |
| 249 | Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model. *Oncotarget*, **2014**, 5, 10916-33 | 3.3 | 21 |
| 248 | Zebrafish embryo as a tool to study tumor/endothelial cell cross-talk. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2013**, 1832, 1371-7 | 6.9 | 39 |
| 247 | TR-644 a novel potent tubulin binding agent induces impairment of endothelial cells function and inhibits angiogenesis. *Angiogenesis*, **2013**, 16, 647-62 | 10.6 | 31 |
| 246 | A novel ex vivo murine retina angiogenesis (EMRA) assay. *Experimental Eye Research*, **2013**, 112, 51-6 | 3.7 | 25 |
| 245 | Involvement of Vβ3 integrin in gremlin-induced angiogenesis. *Angiogenesis*, **2013**, 16, 235-43 | 10.6 | 36 |

| | | | |
|---|---|---|---|
| 244 | Matrigel plug assay: evaluation of the angiogenic response by reverse transcription-quantitative PCR. *Angiogenesis*, **2013**, 16, 469-77 | 10.6 | 36 |
| 243 | Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. *Journal of Pathology*, **2013**, 229, 87-98 | 9.4 | 23 |
| 242 | Ascorbic acid rescues cardiomyocyte development in Fgfr1(-/-) murine embryonic stem cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2013**, 1833, 140-7 | 4.9 | 10 |
| 241 | Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. *Molecular Cancer Therapeutics*, **2013**, 12, 2760-71 | 6.1 | 52 |
| 240 | Inhibition of angiogenesis by β-galactosylceramidase deficiency in globoid cell leukodystrophy. *Brain*, **2013**, 136, 2859-75 | 11.2 | 27 |
| 239 | Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. *Journal of Pathology*, **2013**, 230, 228-38 | 9.4 | 48 |
| 238 | Substrate-immobilized HIV-1 Tat drives VEGFR2/α(v)β(3)-integrin complex formation and polarization in endothelial cells. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, e25-34 | 9.4 | 14 |
| 237 | Role of nanomechanics in canonical and noncanonical pro-angiogenic ligand/VEGF receptor-2 activation. *Journal of the American Chemical Society*, **2012**, 134, 14573-9 | 16.4 | 20 |
| 236 | Anti-angiogenic activity of the flavonoid precursor 4-hydroxychalcone. *European Journal of Pharmacology*, **2012**, 691, 125-33 | 5.3 | 26 |
| 235 | Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction: a biological rheostat for fibroblast growth factor 2-mediated angiogenesis. *Arteriosclerosis, Thrombosis, and Vascular Biology* , **2012**, 32, 696-703 | 9.4 | 54 |
| 234 | Sphingosine-1-phosphate receptor-1 controls venous endothelial barrier integrity in zebrafish. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2012**, 32, e104-16 | 9.4 | 22 |
| 233 | The thymidine phosphorylase inhibitor 5SO-tritylinosine (KIN59) is an antiangiogenic multitarget fibroblast growth factor-2 antagonist. *Molecular Cancer Therapeutics*, **2012**, 11, 817-29 | 6.1 | 19 |
| 232 | The Zebrafish/Tumor Xenograft Angiogenesis Assay **2012**, 253-268 | | |
| 231 | Direct and allosteric inhibition of the FGF2/HSPGs/FGFR1 ternary complex formation by an antiangiogenic, thrombospondin-1-mimic small molecule. *PLoS ONE*, **2012**, 7, e36990 | 3.7 | 33 |
| 230 | Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, e116-27 | 9.4 | 51 |
| 229 | Zebrafish embryo, a tool to study tumor angiogenesis. *International Journal of Developmental Biology*, **2011**, 55, 505-9 | 1.9 | 50 |
| 228 | The natural compound n-butylidenephthalide derived from the volatile oil of Radix Angelica sinensis inhibits angiogenesis in vitro and in vivo. *Angiogenesis*, **2011**, 14, 187-97 | 10.6 | 61 |
| 227 | Long pentraxin-3 inhibits FGF8b-dependent angiogenesis and growth of steroid hormone-regulated tumors. *Molecular Cancer Therapeutics*, **2011**, 10, 1600-10 | 6.1 | 43 |

| | | | |
|---|---|---|---|
| 226 | Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action. *Pharmaceuticals*, **2010**, 3, 1241-1278 | 5.2 | 28 |
| 225 | The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo. *Molecular Cancer Research*, **2010**, 8, 322-34 | 6.6 | 34 |
| 224 | Non-peptidic thrombospondin-1 mimics as fibroblast growth factor-2 inhibitors: an integrated strategy for the development of new antiangiogenic compounds. *Journal of Biological Chemistry*, **2010**, 285, 8733-42 | 5.4 | 61 |
| 223 | Antiangiogenic activity of a neutralizing human single-chain antibody fragment against fibroblast growth factor receptor 1. *Molecular Cancer Therapeutics*, **2010**, 9, 3244-53 | 6.1 | 24 |
| 222 | The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. *Journal of Leukocyte Biology*, **2010**, 87, 365-9 | 6.5 | 7 |
| 221 | Gremlin is a novel agonist of the major proangiogenic receptor VEGFR2. *Blood*, **2010**, 116, 3677-80 | 2.2 | 139 |
| 220 | Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. *Journal of Cellular and Molecular Medicine*, **2010**, 14, 2109-21 | 5.6 | 37 |
| 219 | Nanoliter contact angle probes tumor angiogenic ligand-receptor protein interactions. *Biosensors and Bioelectronics*, **2010**, 26, 1571-5 | 11.8 | 11 |
| 218 | Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. *Sensors*, **2009**, 9, 6471-503 | 3.8 | 16 |
| 217 | A pro-inflammatory signature mediates FGF2-induced angiogenesis. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 2083-2108 | 5.6 | 53 |
| 216 | Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 2061-2068 | 5.6 | 48 |
| 215 | Fibroblast growth factor receptor-1 phosphorylation requirement for cardiomyocyte differentiation in murine embryonic stem cells. *Journal of Cellular and Molecular Medicine*, **2009**, 13, 1489-98 | 5.6 | 7 |
| 214 | Impact of VEGF-dependent tumour micro-environment on EDB fibronectin expression by subcutaneous human tumour xenografts in nude mice. *Journal of Pathology*, **2009**, 219, 455-62 | 9.4 | 17 |
| 213 | Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case. *Immunobiology*, **2009**, 214, 800-10 | 3.4 | 22 |
| 212 | Inflammatory cells and chemokines sustain FGF2-induced angiogenesis. *European Cytokine Network* , **2009**, 20, 39-50 | 3.3 | 90 |
| 211 | HIV-1 Tat and heparan sulfate proteoglycan interaction: a novel mechanism of lymphocyte adhesion and migration across the endothelium. *Blood*, **2009**, 114, 3335-42 | 2.2 | 39 |
| 210 | Fibroblast growth factor-2 antagonist and antiangiogenic activity of long-pentraxin 3-derived synthetic peptides. *Current Pharmaceutical Design*, **2009**, 15, 3577-89 | 3.3 | 29 |
| 209 | Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. *European Cytokine Network*, **2009**, 20, 225-34 | 3.3 | 60 |

| | | | |
|---|---|---|---|
| 208 | Fibroblast growth factor-2 binding to the thrombospondin-1 type III repeats, a novel antiangiogenic domain. *International Journal of Biochemistry and Cell Biology*, **2008**, 40, 700-9 | 5.6 | 59 |
| 207 | alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomers. *Molecular Cancer Therapeutics*, **2008**, 7, 3761-70 | 6.1 | 33 |
| 206 | Modulation of angiogenesis by a tetrameric tripeptide that antagonizes vascular endothelial growth factor receptor 1. *Journal of Biological Chemistry*, **2008**, 283, 34250-9 | 5.4 | 29 |
| 205 | Angiopoietin-1 mediates the proangiogenic activity of the bone morphogenic protein antagonist Drm. *Blood*, **2008**, 112, 1154-7 | 2.2 | 28 |
| 204 | Calcitonin receptor-like receptor guides arterial differentiation in zebrafish. *Blood*, **2008**, 111, 4965-72 | 2.2 | 34 |
| 203 | Fibroblast Growth Factor-2 in Angiogenesis **2008**, 77-88 | | 2 |
| 202 | Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factor. *Blood*, **2007**, 109, 1834-40 | 2.2 | 105 |
| 201 | CEACAM1/VEGF cross-talk during neuroblastic tumour differentiation. *Journal of Pathology*, **2007**, 211, 541-549 | 9.4 | 6 |
| 200 | The zebrafish/tumor xenograft angiogenesis assay. *Nature Protocols*, **2007**, 2, 2918-23 | 18.8 | 183 |
| 199 | Role of the soluble pattern recognition receptor PTX3 in vascular biology. *Journal of Cellular and Molecular Medicine*, **2007**, 11, 723-38 | 5.6 | 146 |
| 198 | Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. *Current Pharmaceutical Design*, **2007**, 13, 2025-44 | 3.3 | 117 |
| 197 | Mammalian tumor xenografts induce neovascularization in zebrafish embryos. *Cancer Research*, **2007**, 67, 2927-31 | 10.1 | 219 |
| 196 | Osteopontin overexpression inhibits in vitro re-endothelialization via integrin engagement. *Journal of Biological Chemistry*, **2007**, 282, 19676-84 | 5.4 | 23 |
| 195 | The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignancies. *Cytokine and Growth Factor Reviews*, **2007**, 18, 327-34 | 17.9 | 71 |
| 194 | Dendritic cell-endothelial cell cross-talk in angiogenesis. *Trends in Immunology*, **2007**, 28, 385-92 | 14.4 | 100 |
| 193 | Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. *Journal of Biological Chemistry*, **2006**, 281, 22605-13 | 5.4 | 93 |
| 192 | Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey. *Endothelium: Journal of Endothelial Cell Research*, **2006**, 13, 93-111 | | 39 |
| 191 | Cutting edge: IL-1beta mediates the proangiogenic activity of osteopontin-activated human monocytes. *Journal of Immunology*, **2006**, 177, 4267-70 | 5.3 | 86 |

| | | | |
|---|---|---|---|
| 190 | Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine. *Journal of Immunology*, **2006**, 176, 12-5 | 5.3 | 193 |
| 189 | The gelatin sponge-chorioallantoic membrane assay. *Nature Protocols*, **2006**, 1, 85-91 | 18.8 | 206 |
| 188 | Biological and molecular properties of a new alpha(v)beta3/alpha(v)beta5 integrin antagonist. *Molecular Cancer Therapeutics*, **2005**, 4, 1670-80 | 6.1 | 70 |
| 187 | Complexity and complementarity of outer membrane protein A recognition by cellular and humoral innate immunity receptors. *Immunity*, **2005**, 22, 551-60 | 32.3 | 226 |
| 186 | Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. *Cytokine and Growth Factor Reviews*, **2005**, 16, 159-78 | 17.9 | 1005 |
| 185 | Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. *Glycobiology*, **2005**, 15, 1C-6C | 5.8 | 45 |
| 184 | Heparin Derivatives and Semisynthetic Biotechnological Heparins as Angiogenesis Inhibitors. *Frontiers in Drug Design and Discovery*, **2005**, 2, 371-391 | | |
| 183 | FGF2-induced upregulation of DNA polymerase-delta p12 subunit in endothelial cells. *Oncogene*, **2005**, 24, 1117-21 | 9.2 | 13 |
| 182 | Regulated expression pattern of gremlin during zebrafish development. *Gene Expression Patterns*, **2005**, 5, 539-44 | 1.5 | 11 |
| 181 | Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing trans-resveratrol derivative 3,5,4Strimethoxystilbene. *Molecular Pharmacology*, **2005**, 67, 1451-9 | 4.3 | 98 |
| 180 | Biotechnological engineering of heparin/heparan sulphate: a novel area of multi-target drug discovery. *Current Pharmaceutical Design*, **2005**, 11, 2489-99 | 3.3 | 47 |
| 179 | Antiangiogenesis by chemotherapeutic agents. *Mini-Reviews in Medicinal Chemistry*, **2005**, 5, 313-7 | 3.2 | 6 |
| 178 | Heparin octasaccharides inhibit angiogenesis in vivo. *Clinical Cancer Research*, **2005**, 11, 8172-9 | 12.9 | 56 |
| 177 | Cutting edge: proangiogenic properties of alternatively activated dendritic cells. *Journal of Immunology*, **2005**, 175, 2788-92 | 5.3 | 107 |
| 176 | Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 1837-42 | 9.4 | 79 |
| 175 | alpha(v)beta3-integrin-dependent activation of focal adhesion kinase mediates NF-kappaB activation and motogenic activity by HIV-1 Tat in endothelial cells. *Journal of Cell Science*, **2005**, 118, 3949-58 | 5.3 | 43 |
| 174 | Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonists. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 71-6 | 9.4 | 33 |
| 173 | Integrin alphavbeta3 as a target for blocking HIV-1 Tat-induced endothelial cell activation in vitro and angiogenesis in vivo. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 2315-20 | 9.4 | 38 |

| | | | |
|---|---|---|---|
| 172 | Recombinant human erythropoietin induces intussusceptive microvascular growth in vivo. *Leukemia*, **2004**, 18, 331-6 | 10.7 | 47 |
| 171 | Undersulfated and glycol-split heparins endowed with antiangiogenic activity. *Journal of Medicinal Chemistry*, **2004**, 47, 838-48 | 8.3 | 78 |
| 170 | Chemically sulfated Escherichia coli K5 polysaccharide derivatives as extracellular HIV-1 Tat protein antagonists. *FEBS Letters*, **2004**, 568, 171-7 | 3.8 | 47 |
| 169 | Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis. *Blood*, **2004**, 104, 92-9 | 2.2 | 157 |
| 168 | Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. *Journal of Immunology*, **2003**, 171, 1085-93 | 5.3 | 115 |
| 167 | Shedding of membrane vesicles mediates fibroblast growth factor-2 release from cells. *Journal of Biological Chemistry*, **2003**, 278, 51911-9 | 5.4 | 85 |
| 166 | Thrombospondin 1 as a scavenger for matrix-associated fibroblast growth factor 2. *Blood*, **2003**, 102, 4399-406 | 2.2 | 70 |
| 165 | Erythropoietin as an angiogenic factor. *European Journal of Clinical Investigation*, **2003**, 33, 891-6 | 4.6 | 106 |
| 164 | Distinct role of fibroblast growth factor-2 and vascular endothelial growth factor on tumor growth and angiogenesis. *American Journal of Pathology*, **2003**, 162, 1913-26 | 5.8 | 146 |
| 163 | Overexpression of cytosolic sialidase Neu2 induces myoblast differentiation in C2C12 cells. *FEBS Letters*, **2003**, 547, 183-8 | 3.8 | 43 |
| 162 | Fibroblast growth factor receptor-1 is essential for in vitro cardiomyocyte development. *Circulation Research*, **2003**, 93, 414-20 | 15.7 | 106 |
| 161 | Heparin derivatives as angiogenesis inhibitors. *Current Pharmaceutical Design*, **2003**, 9, 553-66 | 3.3 | 95 |
| 160 | Cross talk between haematopoiesis and angiogenesis. *Advances in Experimental Medicine and Biology*, **2003**, 522, 25-36 | 3.6 | 1 |
| 159 | The role of fibroblast growth factor-2 in the vascularization of the chick embryo chorioallantoic membrane. *Journal of Cellular and Molecular Medicine*, **2002**, 6, 439-46 | 5.6 | 27 |
| 158 | Anti-angiogenic activity of the purine analog 6-thioguanine. *Leukemia*, **2002**, 16, 1490-9 | 10.7 | 26 |
| 157 | Gene expression profile in fibroblast growth factor 2-transformed endothelial cells. *Oncogene*, **2002**, 21, 2433-40 | 9.2 | 29 |
| 156 | Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. *Oncogene*, **2002**, 21, 3889-97 | 9.2 | 56 |
| 155 | HIV-1 Tat protein and endothelium: from protein/cell interaction to AIDS-associated pathologies. *Angiogenesis*, **2002**, 5, 141-51 | 10.6 | 74 |

| | | | |
|---|---|---|---|
| 154 | Cell membrane GM1 ganglioside is a functional coreceptor for fibroblast growth factor 2. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 4367-72 | 11.5 | 91 |
| 153 | Generation of biologically active angiostatin kringle 1-3 by activated human neutrophils. *Journal of Immunology*, **2002**, 168, 5798-804 | 5.3 | 114 |
| 152 | Fibroblast growth factors and their receptors in hematopoiesis and hematological tumors. *Journal of Hematotherapy and Stem Cell Research*, **2002**, 11, 19-32 | | 48 |
| 151 | Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. *FASEB Journal*, **2002**, 16, 1307-9 | 0.9 | 186 |
| 150 | Pietro M. Gullino and angiogenesis. *Endothelium: Journal of Endothelial Cell Research*, **2002**, 9, 227-30 | | 2 |
| 149 | Short heparin sequences spaced by glycol-split uronate residues are antagonists of fibroblast growth factor 2 and angiogenesis inhibitors. *Biochemistry*, **2002**, 41, 10519-28 | 3.2 | 72 |
| 148 | Arabinose-derived bicyclic amino acids: synthesis, conformational analysis and construction of an □□-selective RGD peptide. *Journal of the Chemical Society, Perkin Transactions 1*, **2002**, 638-644 | | 14 |
| 147 | HIV-1 Tat protein: A target for the development of anti-AIDS therapies. *Drugs of the Future*, **2002**, 27, 481 | 2.3 | 20 |
| 146 | Interaction of Angiogenic Growth Factors with Endothelial Cell Heparan Sulfate Proteoglycans **2002**, 357-385 | | |
| 145 | Paracrine and autocrine effects of fibroblast growth factor-4 in endothelial cells. *Oncogene*, **2001**, 20, 2655-63 | 9.2 | 47 |
| 144 | alpha(v)beta(3) integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. *Experimental Hematology*, **2001**, 29, 993-1003 | 3.1 | 71 |
| 143 | Internalization of HIV-1 tat requires cell surface heparan sulfate proteoglycans. *Journal of Biological Chemistry*, **2001**, 276, 3254-61 | 5.4 | 551 |
| 142 | Cell-mediated delivery of fibroblast growth factor-2 and vascular endothelial growth factor onto the chick chorioallantoic membrane: endothelial fenestration and angiogenesis. *Journal of Vascular Research*, **2001**, 38, 389-97 | 1.9 | 60 |
| 141 | Fibroblast growth factor-2 antagonist activity and angiostatic capacity of sulfated Escherichia coli K5 polysaccharide derivatives. *Journal of Biological Chemistry*, **2001**, 276, 37900-8 | 5.4 | 64 |
| 140 | Pentosan polysulfate as an inhibitor of extracellular HIV-1 Tat. *Journal of Biological Chemistry*, **2001**, 276, 22420-5 | 5.4 | 57 |
| 139 | Activation of endothelial cell mitogen activated protein kinase ERK(1/2) by extracellular HIV-1 Tat protein. *Endothelium: Journal of Endothelial Cell Research*, **2001**, 8, 65-74 | | 37 |
| 138 | Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors. *Cancer Research*, **2001**, 61, 309-17 | 10.1 | 32 |
| 137 | Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. *Cancer Research*, **2001**, 61, 2232-8 | 10.1 | 122 |

| | | | |
|---|---|---|---|
| 136 | Inhibition of fibroblast growth factor-2-induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. *Cancer Research*, **2001**, 61, 5057-64 | 10.1 | 29 |
| 135 | An Italian pioneer in the study of tumor angiogenesis. *Haematologica*, **2001**, 86, 1234-5 | 6.6 | 2 |
| 134 | The discovery of angiogenic factors: a historical review. *General Pharmacology*, **2000**, 35, 227-31 | | 83 |
| 133 | Thrombospondin-1/HIV-1 tat protein interaction: modulation of the biological activity of extracellular Tat. *FASEB Journal*, **2000**, 14, 1917-30 | 0.9 | 25 |
| 132 | Role of fibroblast growth factor-2 in human brain: a focus on development. *International Journal of Developmental Neuroscience*, **2000**, 18, 271-9 | 2.7 | 36 |
| 131 | Nerve growth factor induces sphingomyelin accumulation in pheochromocytoma cells. *FEBS Letters* , **2000**, 472, 143-7 | 3.8 | 1 |
| 130 | Examining new models for the study of autocrine and paracrine mechanisms of angiogenesis through FGF2-transfected endothelial and tumour cells. *Advances in Experimental Medicine and Biology*, **2000**, 476, 7-34 | 3.6 | 7 |
| 129 | Comparative 3d-Morphometry of the Microvascular Unit In Tumors and Normal Tissues: Quantitative Studies on Corrosion Casts. *Microscopy and Microanalysis*, **1999**, 5, 1198-1199 | 0.5 | |
| 128 | Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. *Blood*, **1999**, 93, 3064-3073 | 2.2 | 485 |
| 127 | Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. *Molecular Biology of the Cell*, **1999**, 10, 313-27 | 3.5 | 62 |
| 126 | Different tyrosine autophosphorylation requirements in fibroblast growth factor receptor-1 mediate urokinase-type plasminogen activator induction and mitogenesis. *Molecular Biology of the Cell*, **1999**, 10, 23-33 | 3.5 | 26 |
| 125 | Modulation of fibroblast growth factor-2 receptor binding, signaling, and mitogenic activity by heparin-mimicking polysulfonated compounds. *Molecular Pharmacology*, **1999**, 56, 204-13 | 4.3 | 86 |
| 124 | Multiple interactions of HIV-I Tat protein with size-defined heparin oligosaccharides. *Journal of Biological Chemistry*, **1999**, 274, 28198-205 | 5.4 | 98 |
| 123 | Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. *British Journal of Cancer*, **1999**, 80, 724-32 | 8.7 | 162 |
| 122 | Endogenous and exogenous fibroblast growth factor-2 modulate wound healing in the chick embryo chorioallantoic membrane. *Angiogenesis*, **1999**, 3, 89-95 | 10.6 | 23 |
| 121 | Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. *Journal of Pathology*, **1999**, 188, 76-81 | 9.4 | 39 |
| 120 | Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2. *Journal of Pathology*, **1999**, 189, 590-9 | 9.4 | 29 |
| 119 | Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. *Blood*, **1999**, 93, 2627-2636 | 2.2 | 387 |

| | | | |
|---|---|---|---|
| 118 | Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. *Blood*, **1999**, 93, 2627-2636 | 2.2 | 16 |
| 117 | Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. *Blood*, **1999**, 93, 3064-3073 | 2.2 | 103 |
| 116 | Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. *Journal of Cell Science*, **1999**, 112, 2597-2606 | 5.3 | 35 |
| 115 | In vivo angiogenic activity of urokinase: role of endogenous fibroblast growth factor-2. *Journal of Cell Science*, **1999**, 112, 4213-4221 | 5.3 | 49 |
| 114 | Alterations of blood vessel development by endothelial cells overexpressing fibroblast growth factor-2 **1999**, 189, 590 | | 3 |
| 113 | Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. *Blood*, **1999**, 93, 2627-36 | 2.2 | 123 |
| 112 | Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. *Blood*, **1999**, 93, 3064-73 | 2.2 | 123 |
| 111 | Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process. *Cancer Research*, **1999**, 59, 2417-24 | 10.1 | 36 |
| 110 | Role of endothelial cell extracellular signal-regulated kinase1/2 in urokinase-type plasminogen activator upregulation and in vitro angiogenesis by fibroblast growth factor-2. *Journal of Cell Science*, **1999**, 112 ( Pt 15), 2597-606 | 5.3 | 9 |
| 109 | Developmentally regulated expression and localization of fibroblast growth factor receptors in the human muscle. *Developmental Dynamics*, **1998**, 211, 362-73 | 2.9 | 16 |
| 108 | Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. *International Journal of Clinical and Laboratory Research*, **1998**, 28, 55-68 | | 79 |
| 107 | The basic domain in HIV-1 Tat protein as a target for polysulfonated heparin-mimicking extracellular Tat antagonists. *Journal of Biological Chemistry*, **1998**, 273, 16027-37 | 5.4 | 92 |
| 106 | Noncompetitive, chemokine-mediated inhibition of basic fibroblast growth factor-induced endothelial cell proliferation. *Journal of Biological Chemistry*, **1998**, 273, 7911-9 | 5.4 | 14 |
| 105 | Characterization of the effects of two polysulfonated distamycin A derivatives, PNU145156E and PNU153429, on HIV type 1 Tat protein. *AIDS Research and Human Retroviruses*, **1998**, 14, 1561-71 | 1.6 | 14 |
| 104 | Impact of fibroblast growth factor-2 on tumor microvascular architecture. A tridimensional morphometric study. *American Journal of Pathology*, **1998**, 152, 1607-16 | 5.8 | 33 |
| 103 | Autocrine Role of Basic Fibroblast Growth Factor (bFGF) in Angiogenesis and Angioproliferative Diseases **1998**, 99-112 | | |
| 102 | Role of basic fibroblast growth factor in the formation of the capillary plexus in the chick embryo chorioallantoic membrane. An in situ hybridization, immunohistochemical and ultrastructural study. *Journal of Submicroscopic Cytology and Pathology*, **1998**, 30, 127-36 | | 12 |
| 101 | alphavbeta3 integrin mediates the cell-adhesive capacity and biological activity of basic fibroblast growth factor (FGF-2) in cultured endothelial cells. *Molecular Biology of the Cell*, **1997**, 8, 2449-61 | 3.5 | 130 |

| | | | |
|---|---|---|---|
| 100 | Upregulation of urokinase-type plasminogen activator by endogenous and exogenous HIV-1 Tat protein in tumour cell lines derived from BK virus/tat-transgenic mice. *Aids*, **1997**, 11, 727-36 | 3.5 | 7 |
| 99 | Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation, and size. *Journal of Biological Chemistry*, **1997**, 272, 11313-20 | 5.4 | 157 |
| 98 | New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. *Journal of Vascular Research*, **1997**, 34, 455-63 | 1.9 | 183 |
| 97 | Basic fibroblast growth factor-induced angiogenesis in the chick embryo chorioallantoic membrane: an electron microscopy study. *Microvascular Research*, **1997**, 53, 187-90 | 3.7 | 12 |
| 96 | Urokinase-type plasminogen activator overexpression enhances the invasive capacity of endothelial cells. *Microvascular Research*, **1997**, 53, 254-60 | 3.7 | 16 |
| 95 | Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice. *Angiogenesis*, **1997**, 1, 102-116 | 10.6 | 19 |
| 94 | The italian SSpecial Project on AngiogenesisS *Angiogenesis*, **1997**, 1, 20-1 | 10.6 | |
| 93 | Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium. A study of aortic and microvascular endothelial cell lines. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1997**, 17, 454-64 | 9.4 | 90 |
| 92 | Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. *Circulation Research*, **1997**, 80, 845-52 | 15.7 | 158 |
| 91 | The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. *Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research*, **1997**, 8, 471-9 | | 26 |
| 90 | Angiogenic phenotype induced by basic fibroblast growth factor transfection in brain microvascular endothelial cells. *International Journal of Oncology*, **1996**, 8, 567-73 | 1 | 6 |
| 89 | Role of soluble mediators in angiogenesis. *European Journal of Cancer*, **1996**, 32A, 2401-12 | 7.5 | 72 |
| 88 | Clinical studies with angiogenesis inhibitors: biological rationale and challenges for their evaluation. *Annals of Oncology*, **1996**, 7, 441-4 | 10.3 | 24 |
| 87 | Basic fibroblast growth factor modulates in vitro differentiation of human fetal microglia. *NeuroReport*, **1996**, 7, 2813-7 | 1.7 | 12 |
| 86 | Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. *Aids*, **1996**, 10, 701-10 | 3.5 | 37 |
| 85 | Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. *British Journal of Cancer*, **1996**, 74, 1168-74 | 8.7 | 15 |
| 84 | Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Biological implications in neovascularization. *International Journal of Clinical and Laboratory Research*, **1996**, 26, 15-23 | | 109 |
| 83 | A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells. *Molecular Biology of the Cell*, **1996**, 7, 369-81 | 3.5 | 37 |

| | | | |
|---|---|---|---|
| 82 | Basic Fibroblast Growth Factor Expression in Endothelial Cells: An Autocrine Role in Angiogenesis? **1996**, 61-72 | | |
| 81 | The Interaction of Basic Fibroblast Growth Factor (bFGF) With Heparan Sulfate Proteoglycans **1996**, 171-187 | | 1 |
| 80 | HIV-tat protein is a heparin-binding angiogenic growth factor. *Oncogene*, **1996**, 12, 289-97 | 9.2 | 117 |
| 79 | Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. *Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research*, **1996**, 7, 147-60 | | 21 |
| 78 | Mechanisms of kaposis-sarcoma cell supernatant-induced vascular cell invasion. *International Journal of Oncology*, **1995**, 6, 539-46 | 1 | |
| 77 | Inhibition of inducible nitric oxide synthase mRNA expression by basic fibroblast growth factor in human microglial cells. *Neuroscience Letters*, **1995**, 195, 45-8 | 3.3 | 25 |
| 76 | Expression of basic fibroblast growth factor and its receptors in human fetal microglia cells. *International Journal of Developmental Neuroscience*, **1995**, 13, 29-39 | 2.7 | 40 |
| 75 | Endogenous basic fibroblast growth factor is implicated in the vascularization of the chick embryo chorioallantoic membrane. *Developmental Biology*, **1995**, 170, 39-49 | 3.1 | 147 |
| 74 | Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor. *Journal of Cellular Physiology*, **1995** , 162, 400-9 | 7 | 41 |
| 73 | Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-1-B cells: an export-dependent mechanism of action. *Cancer Research*, **1995**, 55, 4729-38 | 10.1 | 26 |
| 72 | Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. *Cell Growth & Differentiation: the Molecular Biology Journal of the American Association for Cancer Research*, **1995**, 6, 1009-17 | | 16 |
| 71 | Evaluation of the tumor-promoting activity of two beta-adrenoreceptor blocking agents, propranolol and atenolol, in liver of Fischer 344 rats. *Carcinogenesis*, **1994**, 15, 2531-9 | 4.6 | 14 |
| 70 | Inhibition of angiogenesis in rats by IL-1 receptor antagonist and selected cytokine antibodies. *Inflammation*, **1994**, 18, 45-58 | 5.1 | 36 |
| 69 | Interaction of high-molecular-weight basic fibroblast growth factor with endothelium: biological activity and intracellular fate of human recombinant M(r) 24,000 bFGF. *Journal of Cellular Physiology*, **1994**, 161, 149-59 | 7 | 61 |
| 68 | Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. *Biochemical and Biophysical Research Communications*, **1994**, 203, 450-8 | 3.4 | 79 |
| 67 | Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. *Biochemical Journal*, **1994**, 303 ( Pt 2), 583-90 | 3.8 | 38 |
| 66 | Differential expression of fibroblast growth factor receptors by human neurones, astrocytes and microglia. *NeuroReport*, **1994**, 6, 197-200 | 1.7 | 27 |
| 65 | Human Basic Fibroblast Growth Factor: Structure-Function Relationship of an Angiogenic Molecule **1994**, 39-50 | | |

| | | | |
|---|---|---|---|
| 64 | Estro-progestinic replacement therapy modulates the levels of basic fibroblast growth factor (bFGF) in postmenopausal endometrium. *Gynecologic Oncology*, **1993**, 48, 88-93 | 4.9 | 20 |
| 63 | Subcellular localization and biological activity of M(r) 18,000 basic fibroblast growth factor: site-directed mutagenesis of a putative nuclear translocation sequence. *Growth Factors*, **1993**, 9, 269-78 | 1.6 | 15 |
| 62 | The NH2-terminal extension of high molecular weight forms of basic fibroblast growth factor (bFGF) is not essential for the binding of bFGF to nuclear chromatin in transfected NIH 3T3 cells. *Growth Factors*, **1993**, 8, 49-60 | 1.6 | 21 |
| 61 | Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. *Molecular Biology of the Cell*, **1993**, 4, 973-82 | 3.5 | 180 |
| 60 | Basic fibroblast growth factor in human pheochromocytoma: a biochemical and immunohistochemical study. *International Journal of Cancer*, **1993**, 53, 5-10 | 7.5 | 27 |
| 59 | Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors. *Journal of Cellular Physiology*, **1993**, 154, 152-61 | 7 | 78 |
| 58 | Biochemical bases of the interaction of human basic fibroblast growth factor with glycosaminoglycans. New insights from trypsin digestion studies. *FEBS Journal*, **1993**, 214, 51-8 | | 50 |
| 57 | Structure-function relationship of basic fibroblast growth factor: site-directed mutagenesis of a putative heparin-binding and receptor-binding region. *Biochemical and Biophysical Research Communications*, **1992**, 185, 1098-107 | 3.4 | 27 |
| 56 | Activation of the tyrosine kinase receptor is not sufficient for the full biological activity of bFGF. *Exs* , **1992**, 61, 101-6 | | 3 |
| 55 | Basic Fibroblast Growth Factor and Endothelial Cells: Receptor Interaction, Signal Transduction, Cellular Response-Dissociation of the Mitogenic Activity of bFGF from its Plasminogen Activator-Inducing Capacity **1992**, 79-89 | | |
| 54 | Basic fibroblast growth factor bound to cell substrate promotes cell adhesion, proliferation, and protease production in cultured endothelial cells. *Exs*, **1992**, 61, 205-9 | | 7 |
| 53 | Immunoreactive basic fibroblast growth factor-like proteins in chromaffin granules. *Journal of Neurochemistry*, **1991**, 56, 1087-8 | 6 | 9 |
| 52 | Biologically active synthetic fragments of human basic fibroblast growth factor (bFGF): identification of two Asp-Gly-Arg-containing domains involved in the mitogenic activity of bFGF in endothelial cells. *Journal of Cellular Physiology*, **1991**, 149, 512-24 | 7 | 29 |
| 51 | Basic fibroblast growth factor requires a long-lasting activation of protein kinase C to induce cell proliferation in transformed fetal bovine aortic endothelial cells. *Molecular Biology of the Cell*, **1991** , 2, 719-26 | | 59 |
| 50 | A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. *Proceedings of the National Academy of Sciences of the United States of America*, **1991**, 88, 2628-32 | 11.5 | 74 |
| 49 | Nuclear localization of endogenous basic fibroblast growth factor in cultured endothelial cells. *Experimental Cell Research*, **1991**, 192, 505-10 | 4.2 | 55 |
| 48 | Functional domains of basic fibroblast growth factor. Possible role of Asp-Gly-Arg sequences in the mitogenic activity of bFGF. *Annals of the New York Academy of Sciences*, **1991**, 638, 361-8 | 6.5 | 6 |
| 47 | A mutant of basic fibroblast growth factor that has lost the ability to stimulate plasminogen activator synthesis in endothelial cells. *Annals of the New York Academy of Sciences*, **1991**, 638, 369-77 | 6.5 | 1 |

| | | | |
|---|---|---|---|
| 46 | Is the Beta-Blocker DL-ZAMI 1305 a Tumor Promoter for Rat Liver? **1991**, 599-610 | | |
| 45 | Synthesis of urokinase-type plasminogen activator and of type-1 plasminogen activator inhibitor in neuronal cultures of human fetal brain: stimulation by phorbol ester. *Journal of Neurochemistry*, **1990**, 55, 1647-54 | 6 | 30 |
| 44 | Basic fibroblast growth factor in neuronal cultures of human fetal brain. *Journal of Neuroscience Research*, **1990**, 27, 78-83 | 4.4 | 23 |
| 43 | Chemical structure and genotoxic activity of the hepatocarcinogenic beta-blocker DL-ZAMI 1305. *Carcinogenesis*, **1990**, 11, 261-5 | 4.6 | 3 |
| 42 | Basic fibroblast growth factor in ovulatory cycle and postmenopausal human endometrium. *Growth Factors*, **1990**, 3, 299-307 | 1.6 | 49 |
| 41 | Liver genotoxic activity of an epoxide derivative of the hepatocarcinogenic beta-blocker DL-ZAMI 1305. *Cancer Letters*, **1990**, 55, 61-6 | 9.9 | |
| 40 | Characterization of a Mr 20,000 basic fibroblast growth factor-like protein secreted by normal and transformed fetal bovine aortic endothelial cells. *Experimental Cell Research*, **1990**, 186, 354-61 | 4.2 | 19 |
| 39 | Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. *Journal of Cellular Physiology*, **1989**, 140, 68-74 | 7 | 130 |
| 38 | Basic fibroblast growth factor: production, mitogenic response, and post-receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells. *Journal of Cellular Physiology*, **1989**, 141, 517-26 | 7 | 45 |
| 37 | Characterization of a Mr 25,000 basic fibroblast growth factor form in adult, regenerating, and fetal rat liver. *Biochemical and Biophysical Research Communications*, **1989**, 164, 1182-9 | 3.4 | 35 |
| 36 | Induction of plasminogen activator activity by phorbol ester in transformed fetal bovine aortic endothelial cells. Possible independence from protein kinase C. *Biochemical and Biophysical Research Communications*, **1989**, 160, 682-91 | 3.4 | 11 |
| 35 | The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. *Journal of Cell Biology*, **1989**, 109, 1877-84 | 7.3 | 116 |
| 34 | Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. *Journal of Cellular Physiology*, **1988**, 137, 593-7 | 7 | 80 |
| 33 | Multiple forms of an angiogenesis factor: basic fibroblast growth factor. *Biochimie*, **1988**, 70, 83-7 | 4.6 | 49 |
| 32 | Purification of basic fibroblast growth factor from rat brain: identification of a Mr 22,000 immunoreactive form. *Biochemical and Biophysical Research Communications*, **1988**, 155, 1161-72 | 3.4 | 51 |
| 31 | High molecular weight immunoreactive basic fibroblast growth factor-like proteins in rat pituitary and brain. *Neuroscience Letters*, **1988**, 90, 308-13 | 3.3 | 29 |
| 30 | New aspects of blood vessel growth: tumor and tissue-derived angiogenesis factors. *Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research*, **1988**, 18, 6-17 | | 4 |
| 29 | Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells by basic fibroblast growth factor and transforming growth factor beta. *Cancer Research*, **1988**, 48, 6384-9 | 10.1 | 34 |

| | | | |
|---|---|---|---|
| 28 | Liver DNA Damage by Chemical Carcinogens: Role of Thyroid Hormones **1988**, 129-135 | | |
| 27 | A form of human basic fibroblast growth factor with an extended amino terminus. *Biochemical and Biophysical Research Communications*, **1987**, 144, 543-50 | 3.4 | 103 |
| 26 | Critical role of gonadal hormones on the genotoxic activity of the hepatocarcinogen DL-ZAMI 1305. *Cancer Letters*, **1987**, 36, 253-61 | 9.9 | 5 |
| 25 | Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. *Proceedings of the National Academy of Sciences of the United States of America*, **1986**, 83, 2091-5 | 11.5 | 314 |
| 24 | Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. *Molecular and Cellular Biology*, **1986**, 6, 4060-6 | 4.8 | 252 |
| 23 | Both normal and tumor cells produce basic fibroblast growth factor. *Journal of Cellular Physiology*, **1986**, 129, 273-6 | 7 | 217 |
| 22 | Further studies on the tumor-initiating activity of the beta-blocker DL-ZAMI 1305. *Toxicologic Pathology*, **1986**, 14, 470-6 | 2.1 | 1 |
| 21 | Purification and biological activities of an angiogenesis factor from human placenta. *Anticancer Research*, **1986**, 6, 861-3 | 2.3 | 9 |
| 20 | Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. *Molecular and Cellular Biology*, **1986**, 6, 4060-4066 | 4.8 | 65 |
| 19 | Human placental tissue stimulates bovine capillary endothelial cell growth, migration and protease production. *Bioscience Reports*, **1985**, 5, 783-90 | 4.1 | 23 |
| 18 | Inhibition of DNA and RNA synthesis in rat liver nuclei by oncogenic and non-oncogenic beta-blockers. *Toxicologic Pathology*, **1985**, 13, 18-25 | 2.1 | 3 |
| 17 | Thyroid and chemical hepatocarcinogenesis: further insights from the hepatocarcinogen ZAMI 1305. *Toxicologic Pathology*, **1984**, 12, 49-55 | 2.1 | 2 |
| 16 | Early liver alterations induced by the sex-dependent hepatocarcinogen beta-blocker ZAMI 1305. *Chemico-Biological Interactions*, **1984**, 52, 203-12 | 5 | 2 |
| 15 | Optical isomers of the hepatocarcinogenic beta-blocker ZAMI 1305: influence on nucleic acids synthesis and DNA integrity. *Chemico-Biological Interactions*, **1984**, 50, 77-86 | 5 | 4 |
| 14 | Age-dependent, seasonal and daily variations of the DNA damaging capacity of the hepatocarcinogen ZAMI 1305 in female rat liver. *Cancer Letters*, **1984**, 23, 245-51 | 9.9 | 5 |
| 13 | Tumor-initiating activity of the beta-blocker ZAMI 1305 in the liver of the female Wistar rat. *Cancer Letters*, **1984**, 25, 1-11 | 9.9 | 5 |
| 12 | Embryonic----Fetal Hb switch in humans: studies on erythroid bursts generated by embryonic progenitors from yolk sac and liver. *Proceedings of the National Academy of Sciences of the United States of America*, **1984**, 81, 2416-20 | 11.5 | 45 |
| 11 | Thyroid modifications in male and female rats treated with the hepatocarcinogen beta-blocker ZAMI 1305. *Cancer Letters*, **1983**, 19, 293-9 | 9.9 | 4 |

| | | | |
|---|---|---|---|
| 10 | In vitro inhibition of rat liver DNA polymerases □and □by □blockers. *Bioscience Reports*, **1983**, 3, 299-308 | 4.1 | 5 |
| 9 | In vitro and in vivo DNA damage of male and female rat liver nuclei by oncogenic and nononcogenic beta blockers. *Journal of the National Cancer Institute*, **1983**, 70, 747-52 | 9.7 | 16 |
| 8 | Preferential induction of fetal versus embryonic globin chains in human leukemic cell lines. *Leukemia Research*, **1982**, 6, 155-63 | 2.7 | 6 |
| 7 | Inhibition in vitro of yeast DNA polymerase I activity by beta-blockers. *Bioscience Reports*, **1982**, 2, 55-62 | 4.1 | 4 |
| 6 | Liver tumors induced by a new beta-adrenoreceptor blocking agent in female rats. *Journal of the National Cancer Institute*, **1982**, 68, 669-72 | 9.7 | 18 |
| 5 | Liver growth after partial hepatectomy: influence of phenobarbital administration. *Experimental and Molecular Pathology*, **1981**, 34, 216-25 | 4.4 | 1 |
| 4 | Quantification of damage to striated muscle after normothermic or hypothermic ischemia. *Clinical Chemistry*, **1981**, 27, 297-302 | 5.5 | 3 |
| 3 | Decrease of the activity of the mixed function oxidase system in regenerating rat liver: an alternative explanation. *Biochemical and Biophysical Research Communications*, **1980**, 95, 829-34 | 3.4 | 17 |
| 2 | Inhibition of protein synthesis in ischaemic liver from phenobarbitone-treated rat. *Experientia*, **1979**, 35, 86-8 | | 3 |
| 1 | Gene expression profile in fibroblast growth factor 2-transformed endothelial cells | | 1 |